[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
April 2011

Targets of the Peroxisome Proliferator–Activated Receptor γ Agonist Trials for the Prevention of Alzheimer Disease—Reply

Author Affiliations

Author Affiliations: Department of Neurology, University of Virginia Health System, Charlottesville (Dr Geldmacher); Parkinson Research Institute, Aurora Sinai Medical Center, Milwaukee, Wisconsin (Dr Fritsch); and the Alzheimer's Research Laboratory, Department of Neuroscience, Case Western Reserve University, Cleveland, Ohio (Dr Landreth).

Arch Neurol. 2011;68(4):542-543. doi:10.1001/archneurol.2011.58

In reply

We thank Dr Sakurai for his insightful comments. The observation that pioglitazone was associated with improvement in clinical and biomarker outcomes in patients with AD and diabetes mellitus reinforces the potential value of this line of therapeutics.1 There is increased risk for AD among patients with diabetes.2 Taken together, these observations suggest additional means of enriching samples for future trials of PPARγ agonists and other insulin-sensitizing agents beyond the typical APOE genotyping. We also concur that these agents are likely to be most useful in prevention, rather than response to, symptomatically expressed AD. Therefore, trials of patients with mild cognitive impairment (or biomarker evidence of incipient AD) and relative insulin resistance might have the highest likelihood of detecting clinical efficacy for insulin-sensitizing drugs as antidementia agents.

First Page Preview View Large
First page PDF preview
First page PDF preview
×